Our latest Investing Matters Podcast episode with QuotedData's Edward Marten has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCambridge Cog Regulatory News (COG)

Share Price Information for Cambridge Cog (COG)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 54.50
Bid: 54.00
Ask: 55.00
Change: 0.00 (0.00%)
Spread: 1.00 (1.852%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 55.00
COG Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Update

16 Mar 2016 07:00

RNS Number : 1982S
Cambridge Cognition Holdings PLC
16 March 2016
 

 

 

Cambridge Cognition Holdings Plc

('Cambridge Cognition' or the 'Company')

 

Trading Update

 

Cambridge Cognition Holdings plc, (AIM: COG), the specialist developer of computerised tests for detection and monitoring of neuropsychological disorders, announces a trading update.

 

In November 2015 the Company announced that it expected to end the financial year to 31st December 2015 by announcing three new major pharmaceutical clinical trial contracts totaling US$4.5m with upfront payments and revenues to be recognised through to 2017. During 2015 the Company secured an increased number of clinical trial contracts in both the pharmaceutical and academic businesses whilst also making an increased investment in sales and marketing operations.

 

The pharmaceutical partner for one of the three large studies announced in November has informed the Company of delays in initiating the planned clinical study due to regulatory reviews. This has resulted in the trial initiation revenue for this study shifting from 2015 to 2016.

 

In addition, the Company incurred one-off costs in late 2015 related to the potential expansion of the healthcare technology platform.

 

The impact of the above is that the loss incurred in 2015 is now expected to be approximately £0.6m, before the exceptional costs of £0.2m. The preliminary results for the year will be released towards the end of April 2016.

 

Commenting on the announcement Steven Powell, Chief Executive Officer, said: "Despite not quite meeting earnings expectations for 2015, 2016 has got off to a good start with an encouraging sales pipeline. This reflects our revised strategy and renewed focus on accelerating software revenues through our pharmaceutical and academic businesses and commercialising our healthcare technologies through partnerships. We look forward to announcing further progress with our results in April."

 

 

 

Enquiries:

 

Cambridge Cognition Holdings plc

www.cambridgecognition.com

Steven Powell, Chief Executive Officer

Tel: 01223 810 700

Nick Walters, Chief Financial Officer

finnCap Ltd (Nomad and Broker)

Tel: 020 7220 0500

Geoff Nash/Simon Hicks

(Corporate Finance)

Malar Velaigam

(Corporate Broking)

 

 

About Cambridge Cognition

Cambridge Cognition is a world leading provider of computerised cognitive assessment products. The company's range of touch-screen CANTAB™ neuropsychological tests, highly validated over one thousand peer-reviewed publications, are used by both academic scientists in their research, and clinical researchers in the pharmaceutical industry, to maximise knowledge of cognitive function. In addition, the company is committed to broadening the access to this technology and is developing clinical healthcare products to improve the monitoring, management and maintenance of cognitive health and wellbeing. Using these assessments, clinicians can identify and stratify patients so that patient referrals are accurate and efficient, enabling health and social care providers to deliver more effective advice, treatments and care - leading to better outcomes for patients and their families.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTSFUFMIFMSEED
Date   Source Headline
21st Mar 20247:00 amRNSFormation of new Scientific Advisory Board
21st Feb 202410:16 amRNSHolding(s) in Company
21st Feb 20247:00 amRNSCambridge Cognition and ActiGraph Partnership
30th Jan 20244:20 pmRNSDirector/PDMR Share Purchases
30th Jan 20247:00 amRNSBoard appointments
30th Jan 20247:00 amRNSTrading Update
18th Dec 20237:00 amRNSGrant of Options
1st Dec 20237:00 amRNSTotal Voting Rights
22nd Nov 20237:00 amRNSChange of Auditor
1st Nov 20237:00 amRNSTotal Voting Rights
24th Oct 20237:00 amRNSAutomated quality assurance for clinical trials
11th Oct 20237:00 amRNSMajor contract win combining solutions
5th Oct 20235:33 pmRNSIssue of Warrants
3rd Oct 20232:43 pmRNSBlock listing Interim Review
28th Sep 20233:35 pmRNSHolding(s) in Company
26th Sep 20237:01 amRNSInterim Results
26th Sep 20237:00 amRNSSecured £3 million Term Loan
4th Sep 20237:00 amRNSNotice of Interim Results
3rd Jul 20237:00 amRNSTotal Voting Rights
28th Jun 20234:26 pmRNSResult of AGM
13th Jun 20237:00 amRNS£2m contract for a pivotal cancer therapy trial
9th Jun 20237:00 amRNSNotice of AGM – Revision to Explanatory Note
6th Jun 20237:00 amRNSPosting of Annual Report & Notice of AGM
31st May 20237:00 amRNSCapital Markets Day
3rd May 20237:00 amRNSResults for the year ended 31 December 2022
26th Apr 20237:00 amRNSInvestor Webinar and Analyst Briefing
20th Apr 20237:00 amRNSNotice of Results
12th Apr 20237:00 amRNS£2.1 million contracts for rare disease trials
21st Mar 20237:00 amRNSBlock Admission Application & Exercise of Options
6th Feb 20237:00 amRNSDirector/PDMR Share Purchases
31st Jan 20237:00 amRNSTrading Update
30th Jan 20231:14 pmRNSHolding(s) in Company
18th Jan 20231:14 pmRNSHolding(s) in Company
18th Jan 202312:22 pmRNSHolding(s) in Company
17th Jan 20235:54 pmRNSHolding(s) in Company
17th Jan 20234:06 pmRNSHolding(s) in Company
13th Jan 20235:09 pmRNSHolding(s) in Company
11th Jan 20237:00 amRNSAcquisition of Winterlight Labs Inc
24th Nov 20227:00 amRNSStrategic Partnership for Chinese Market Expansion
19th Oct 20227:00 amRNS£1.1 million eCOA contract win
12th Oct 20227:00 amRNSAcquisition of eClinicalHealth Limited
20th Sep 20227:00 amRNSInterim Results
1st Sep 20227:00 amRNS£2.2m neurodegenerative disease trial contract
17th Aug 20227:00 amRNSAlzheimer’s Disease Validation for NeuroVocalix
3rd Aug 20222:55 pmRNSDirectorate Change
28th Jul 20227:00 amRNSPTSD trials with top 10 pharma company & US DoD
26th Jul 20227:00 amRNSGrant of Options
22nd Jul 202211:05 amRNSSecond Price Monitoring Extn
22nd Jul 202211:00 amRNSPrice Monitoring Extension
22nd Jul 20227:00 amRNSDirector/PDMR Share Purchases

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.